Teledoc (TDOC) Gets a $7 Price Target From Barclays: Can It Double From Recent Lows?

Teladoc Health (NYSE:TDOC) has staged a notable recovery off its lows, but the stock remains under significant pressure from its longer-term trajectory. Shares are up 1.37% over the past week and have gained 3.83% over the past month, yet they remain down 21.21% year-to-date and nearly 36% over the past year.

The stock sits well below its 52-week high of $9.77, and its five-year decline of 96.85% from a peak near $176.89 tells the broader story of a company still searching for its footing. Most analysts maintain cautious stances, with the Street consensus target at $7.12 and 21 of 27 analysts rating the stock a Hold.

Barclays recently cut its price target on Teladoc to $7 from $8.50, maintaining an Equal Weight rating following a meeting with management. From the current price of $5.57, that target still implies upside of more than 25%, landing nearly in line with the broader Street consensus. But can TDOC realistically reach $7 by end of 2026?

Barclays’ $7 TDOC Prediction

Barclays acknowledges pockets of optimism in the business, particularly in International and the insured side of BetterHelp, but frames its cautious stance around a company transitioning its model in a competitive segment of the market. That transition is visible in the numbers: BetterHelp revenue fell 7% year-over-year in Q4 2025, and 2026 guidance calls for BetterHelp revenue to decline a further 0.5% to 7.0% as the segment shifts toward insurance-based delivery.

Key Drivers of TDOC Stock Performance

1. BetterHelp Insurance Scaling: The company is now live in 20 states plus Washington, D.C. with more than 120 million covered lives secured. Insurance sessions are generating an annualized revenue run rate of over $40 million, with a 2026 target of $75 million to $90 million.
2. International Revenue Growth: International revenue surged 19% year-over-year to $125 million in Q4 2025, representing nearly 24% of total segment revenue for full-year 2025.
3. Improving Profitability Trajectory: Adjusted EBITDA improved 12% to $83.8 million in Q4, and the company generated $167 million in free cash flow for full-year 2025. Net loss narrowed 48% year-over-year in the quarter.

What Will It Take for TDOC to Reach $7?

With 178.4 million shares outstanding, a $7 price target implies a market capitalization approaching $1.25 billion, roughly double where the stock traded at its post-earnings low. Getting there requires the BetterHelp insurance ramp to gain traction, Integrated Care membership to stabilize within its guided range of 97 million to 100 million members, and the subscription-to-visit model transition to begin moderating top-line pressure as CEO Chuck Divita has projected.

The primary risk is that BetterHelp’s cash-pay business erodes faster than insurance revenue can replace it, leaving the company in a prolonged revenue trough. At a price-to-sales ratio of just 0.39x and with a strengthening balance sheet following the $550.6 million convertible note repayment, the Barclays $7 target reflects a credible recovery path for investors willing to hold through the model transition.